$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000117184318007788 Filed on November 08, 2018

Income Statement

Concept	2018 Q3	2017 Q3
Revenue	$1.454M	$8.760M
YoY Change	-83.4%	12.84%
Cost Of Revenue		$1.142M
YoY Change
Gross Profit	$1.454M	$7.618M
YoY Change	-80.91%	-1.87%
Gross Profit Margin	100.0%	86.96%
Selling, General & Admin	$7.923M	$3.343M
YoY Change	137.0%	21.3%
% of Gross Profit	544.91%	43.88%
Research & Development	$22.01M	$17.51M
YoY Change	25.68%	24.13%
% of Gross Profit	1513.48%	229.84%
Depreciation & Amortization	$190.0K	$180.0K
YoY Change	5.56%	5.88%
% of Gross Profit	13.07%	2.36%
Operating Expenses	$29.93M	$20.85M
YoY Change	43.53%	23.67%
Operating Profit	-$28.49M	-$13.35M
YoY Change	113.45%	44.45%
Interest Expense	$2.346M	$2.140M
YoY Change	9.63%	46.08%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$29.60M	-$15.13M
YoY Change	95.64%	31.22%
Income Tax
% Of Pretax Income
Net Earnings	-$29.60M	-$15.13M
YoY Change	95.57%	31.28%
Net Earnings / Revenue	-2035.56%	-172.76%
Basic Earnings Per Share
Diluted Earnings Per Share	-$280.8K	-$181.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding	105.4M	83.57M

Balance Sheet

Concept	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$120.3M	$161.6M
YoY Change	-25.55%	205.98%
Cash & Equivalents	$52.58M	$117.8M
Short-Term Investments	$67.74M	$43.85M
Other Short-Term Assets	$3.900M	$4.700M
YoY Change	-17.02%	30.56%
Inventory	$821.0K
Prepaid Expenses
Receivables	$3.394M	$8.985M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$128.5M	$175.4M
YoY Change	-26.73%	171.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.236M	$9.613M
YoY Change	-3.92%	-4.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$29.20M	$4.500M
YoY Change	548.89%	-68.75%
Other Assets	$1.420M	$1.955M
YoY Change	-27.37%	-10.73%
Total Long-Term Assets	$39.81M	$16.12M
YoY Change	146.95%	-40.0%
TOTAL ASSETS
Total Short-Term Assets	$128.5M	$175.4M
Total Long-Term Assets	$39.81M	$16.12M
Total Assets	$168.3M	$191.5M
YoY Change	-12.11%	109.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.911M	$4.603M
YoY Change	71.87%	66.78%
Accrued Expenses	$15.12M	$11.87M
YoY Change	27.37%	10.1%
Deferred Revenue
YoY Change
Short-Term Debt	$29.00M	$28.60M
YoY Change	1.4%	1.78%
Long-Term Debt Due	$1.700M	$4.800M
YoY Change	-64.58%
Total Short-Term Liabilities	$64.36M	$69.24M
YoY Change	-7.05%	34.39%
LONG-TERM LIABILITIES
Long-Term Debt	$31.00M	$21.10M
YoY Change	46.92%	-16.6%
Other Long-Term Liabilities	$100.0K	$500.0K
YoY Change	-80.0%	-95.28%
Total Long-Term Liabilities	$31.10M	$21.60M
YoY Change	43.98%	-39.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$64.36M	$69.24M
Total Long-Term Liabilities	$31.10M	$21.60M
Total Liabilities	$95.40M	$90.90M
YoY Change	4.95%	3.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$704.5M	-$612.3M
YoY Change	15.06%	9.04%
Common Stock	$1.096M	$984.0K
YoY Change	11.38%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.87M	$100.6M
YoY Change
Total Liabilities & Shareholders Equity	$168.3M	$191.5M
YoY Change	-12.11%	109.28%

Cashflow Statement

Concept	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$29.60M	-$15.13M
YoY Change	95.57%	31.28%
Depreciation, Depletion And Amortization	$190.0K	$180.0K
YoY Change	5.56%	5.88%
Cash From Operating Activities	-$35.03M	-$12.43M
YoY Change	181.82%	-29.17%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$190.0K
YoY Change	-78.95%	5.56%
Acquisitions
YoY Change
Other Investing Activities	-$9.480M	$4.390M
YoY Change	-315.95%	-80.16%
Cash From Investing Activities	-$9.520M	$4.200M
YoY Change	-326.67%	-80.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$53.40M	$86.25M
YoY Change	-38.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	63.92M	86.31M
YoY Change	-25.94%	286.52%
NET CHANGE
Cash From Operating Activities	-35.03M	-12.43M
Cash From Investing Activities	-9.520M	4.200M
Cash From Financing Activities	63.92M	86.31M
Net Change In Cash	19.37M	78.08M
YoY Change	-75.19%	192.11%
FREE CASH FLOW
Cash From Operating Activities	-$35.03M	-$12.43M
Capital Expenditures	-$40.00K	-$190.0K
Free Cash Flow	-$34.99M	-$12.24M
YoY Change	185.87%	-29.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	152000
	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	125000
CY2018Q3	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	432000
CY2017Q4	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	412000
CY2018Q3	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	29157000
CY2017Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	34257000
CY2018Q3	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears
CY2017Q4	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears	7038000
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q3	bcrx	Business Combination Agreement Terminated Expected Transactionrelated Expenses BusinessCombinationAgreementTerminatedExpectedTransactionrelatedExpenses	6000000
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-144000
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-51000
CY2018Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	1973000
CY2018Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive	25000
CY2018Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	1451000
CY2018Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	3434000
CY2018Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	5910000
	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations	-56000
	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations	139000
CY2018Q3	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent	2704000
CY2017Q4	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent	2751000
CY2017Q4	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	200000000
	bcrx	Number Of Stockbased Compensation Plans NumberOfStockbasedCompensationPlans	2
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7911000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6337000
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3394000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6117000
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15120000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12699000
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-410000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-243000
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	776724000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	714869000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7072000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10307000
CY2018Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	222000
CY2017Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	219000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	676000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	658000
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2475000
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1996000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2071000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2519000
CY2018Q3	us-gaap	Assets Assets	168308000
CY2017Q4	us-gaap	Assets Assets	178259000
CY2018Q3	us-gaap	Assets Current AssetsCurrent	128495000
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109625000
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98411000
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	1096000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	984000
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29555000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109625000
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98411000
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	96872000
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	105241000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	97248000
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	125391000
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	410000
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	244000
CY2018Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	67737000
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	64115000
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	96894000
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	105410000
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	67737000
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	64115000
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	29157000
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	41295000
CY2018Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	66000
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	75000
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52584000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50282000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	53568000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23650000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54090000
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120898000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	522000
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15136000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73987000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46244000
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1142000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1142000
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	29947000
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	22109000
	us-gaap	Costs And Expenses CostsAndExpenses	86882000
	us-gaap	Costs And Expenses CostsAndExpenses	60846000
CY2018Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	8000
CY2017Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	210000
CY2018Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	152000
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	81000
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	155000
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	200000
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8484000
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7300000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	572000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	522000
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12793000
CY2018Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	631000
CY2017Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	130000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	334000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-892000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1063000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2723000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	217000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3947000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1303000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-7100000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1224000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-606000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-1858000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1668000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1715000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	821000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-500000
CY2018Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	611000
CY2017Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	225000
	us-gaap	Interest And Other Income InterestAndOtherIncome	1566000
	us-gaap	Interest And Other Income InterestAndOtherIncome	537000
CY2018Q3	us-gaap	Interest Expense InterestExpense	2346000
CY2017Q3	us-gaap	Interest Expense InterestExpense	2140000
	us-gaap	Interest Expense InterestExpense	6762000
	us-gaap	Interest Expense InterestExpense	6334000
CY2018Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	2346000
CY2017Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	2140000
	us-gaap	Interest Expense Debt InterestExpenseDebt	6762000
	us-gaap	Interest Expense Debt InterestExpenseDebt	6334000
CY2018Q3	us-gaap	Interest Payable Current InterestPayableCurrent	10427000
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	12095000
CY2018Q3	us-gaap	Inventory Net InventoryNet	821000
CY2017Q4	us-gaap	Inventory Net InventoryNet
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39550000
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1420000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2027000
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	42000
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	168308000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	178259000
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	64357000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74836000
CY2018Q3	us-gaap	Line Of Credit LineOfCredit	28293000
CY2017Q4	us-gaap	Line Of Credit LineOfCredit	16750000
CY2018Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1621000
CY2017Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	6464000
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	30000000
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1000000
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	12000000
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	12000000
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5000000
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	0
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61167000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	135130000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7935000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7258000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68580000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30624000
	us-gaap	Net Income Loss NetIncomeLoss	-73820000
	us-gaap	Net Income Loss NetIncomeLoss	-46239000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-29597000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-15134000
CY2018Q3	us-gaap	Notes Payable Current NotesPayableCurrent	29012000
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	28682000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-28493000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13349000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-68958000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-167000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	43158000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	39572000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	262000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	32527000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1495000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1491000
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9236000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9546000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	213000
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2445000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1381000
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53400000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53400000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	133500000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	10353000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	51355000
CY2018Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	3394000
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	6117000
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	1000
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	4025000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22006000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17509000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61457000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50038000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17924000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	21296000
CY2018Q3	us-gaap	Royalty Expense RoyaltyExpense	18000
CY2017Q3	us-gaap	Royalty Expense RoyaltyExpense	115000
	us-gaap	Royalty Expense RoyaltyExpense	401000
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1506000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3286000
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-704537000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-631843000
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-630717000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1454000
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8760000
	us-gaap	Royalty Expense RoyaltyExpense	431000
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7923000
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3343000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25024000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9235000
	us-gaap	Share Based Compensation ShareBasedCompensation	7072000
	us-gaap	Share Based Compensation ShareBasedCompensation	10307000
CY2018Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.50
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10454546
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	72873000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	83767000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div>
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105410000
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83570000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100955000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79749000

Files In Submission

Name	View Source	Status
0001171843-18-007788-index-headers.html	Edgar Link	pending
0001171843-18-007788-index.html	Edgar Link	pending
0001171843-18-007788.txt	Edgar Link	pending
0001171843-18-007788-xbrl.zip	Edgar Link	pending
bcrx-20180930.xml	Edgar Link	completed
bcrx-20180930.xsd	Edgar Link	pending
bcrx-20180930_cal.xml	Edgar Link	unprocessable
bcrx-20180930_def.xml	Edgar Link	unprocessable
bcrx-20180930_lab.xml	Edgar Link	unprocessable
bcrx-20180930_pre.xml	Edgar Link	unprocessable
exh101_01.jpg	Edgar Link	pending
exh101_02.jpg	Edgar Link	pending
exh102_01.jpg	Edgar Link	pending
exh102_02.jpg	Edgar Link	pending
exh102_03.jpg	Edgar Link	pending
exh102_04.jpg	Edgar Link	pending
exh102_05.jpg	Edgar Link	pending
exh102_06.jpg	Edgar Link	pending
exh102_07.jpg	Edgar Link	pending
exh102_08.jpg	Edgar Link	pending
exh102_09.jpg	Edgar Link	pending
exh102_10.jpg	Edgar Link	pending
exh102_11.jpg	Edgar Link	pending
exh102_12.jpg	Edgar Link	pending
exh102_13.jpg	Edgar Link	pending
exh102_14.jpg	Edgar Link	pending
exh102_15.jpg	Edgar Link	pending
exh102_16.jpg	Edgar Link	pending
exh102_17.jpg	Edgar Link	pending
exh102_18.jpg	Edgar Link	pending
exh102_19.jpg	Edgar Link	pending
exh102_20.jpg	Edgar Link	pending
exh102_21.jpg	Edgar Link	pending
exh102_22.jpg	Edgar Link	pending
exh102_23.jpg	Edgar Link	pending
exh102_24.jpg	Edgar Link	pending
exh102_25.jpg	Edgar Link	pending
exh102_26.jpg	Edgar Link	pending
exh103_01.jpg	Edgar Link	pending
exh103_02.jpg	Edgar Link	pending
exh_101.htm	Edgar Link	pending
exh_102.htm	Edgar Link	pending
exh_103.htm	Edgar Link	pending
exh_105.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_110818p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2018 Q3 Form 10-Q Financial Statement

#000117184318007788 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2018 Q3 Form 10-Q Financial Statement

#000117184318007788 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx